Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Abeona Therapeutics Inc. (NASDAQ: ABEO).

Full DD Report for ABEO

You must become a subscriber to view this report.


Recent News from (NASDAQ: ABEO)

Abeona Reports Update from EB-101 Gene Therapy in Epidermolysis Bullosa at 21st Annual ASGCT Meeting
NEW YORK and CLEVELAND, May 17, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening, rare, genetic diseases, announced today updated clinical data from th...
Source: GlobeNewswire
Date: May, 17 2018 09:20
Bluebird Bio: Gene Therapy Best In Class
I can confirm that we're at the early stages of a transformation in medical treatment as a consequence of this new technology. FDA commissioner Scott Gottlieb oral testimony This article is part of a series on genomic medicine which is poised to transform healthcare over the next two...
Source: SeekingAlpha
Date: May, 16 2018 11:31
Reader Inquiry: Is There Further Upside Ahead For Rocket Pharmaceuticals?
Shares of gene therapy newcomer Rocket Pharmaceuticals ( RCKT ) have risen by over 80% year to date. The formerly private company came into existence (on the stock exchange) after a merger with floundering biotech firm Inotek Pharma in which shareholders of the former owned 81% of the combined...
Source: SeekingAlpha
Date: May, 15 2018 14:48
Abeona Therapeutics' (ABEO) CEO Carsten Thiel on Q1 2018 Results - Earnings Call Transcript
Abeona Therapeutics, Inc. (ABEO) Q1 2018 Earnings Conference Call May 14, 2018 10:00 AM ET Executives Christine Silverstein – Senior Vice President, Finance and Investor Relations Carsten Thiel – Chief Executive Officer Tim Miller – President and Chief Scient...
Source: SeekingAlpha
Date: May, 14 2018 15:45
Genomic Medicine: Catch The Gene Therapy Wave
Genomic medicine is the future of healthcare. Spawned by the Human Genome Project “HGP” this precise and personal approach to medicine is an emerging discipline with enormous disruptive potential. Though nascent, Genomic medicine is showing signs of being the transformative for...
Source: SeekingAlpha
Date: May, 14 2018 15:12
JF's Core Biotech Buys #15: Removal Of A Key Overhang, Buying Weakness In I-O, Updates And Adding To 2 Positions
Welcome to the fifteenth edition in the series "JF's Core Biotech Buys." Our model account utilizes a full position size of $5,000 and will hold up to 20 stocks. Trades will be less frequent with cost averages calculated at the day's close when an article is published. Depending on the size ...
Source: SeekingAlpha
Date: May, 14 2018 11:37
Abeona Therapeutics Announces Appointment of Stefano Buono and Richard Van Duyne to its Board of Directors
NEW YORK and CLEVELAND, May 14, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced that it is expanding its Board ...
Source: GlobeNewswire
Date: May, 14 2018 08:15
Abeona Therapeutics beats by $0.01, beats on revenue
Abeona Therapeutics (NASDAQ: ABEO ): Q1 EPS of -$0.18 beats by $0.01 . More news on: Abeona Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: May, 11 2018 08:20
Abeona Therapeutics Reports First Quarter 2018 Financial Results and Business Highlights
NEW YORK and CLEVELAND, May 11, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced financial results for the first...
Source: GlobeNewswire
Date: May, 11 2018 08:15
Abeona Therapeutics Announces Upcoming Presentations
NEW YORK and CLEVELAND, May 08, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical- stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced upcoming presentations during ...
Source: GlobeNewswire
Date: May, 08 2018 08:15

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1721.0021.4521.4520.00883,056
2017-06-204.754.904.954.75127,532
2017-06-194.704.804.954.70138,505
2017-06-164.704.704.854.55191,091
2017-06-154.954.755.054.70146,776

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-1734,11970,21748.5908Short
2018-08-1639,477112,59635.0607Short
2018-08-1530,870281,03910.9842Cover
2018-08-1446,86996,09648.7731Short
2018-08-1353,074114,56346.3273Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ABEO.


About Abeona Therapeutics Inc. (NASDAQ: ABEO)

Logo for Abeona Therapeutics Inc. (NASDAQ: ABEO)

Access Pharmaceuticals, Inc. is an emerging pharmaceutical company focused on the development and commercialization of proprietary products for the treatment and supportive care of cancer patients. Access has one approved product, two products in Phase development, and five preclinical development programs. The company s approved product is MuGard TM for the management of oral mucositis a common and debilitating side effect of many cancer therapies for which marketing authorization has been allowed by the FDA. Access ProLindac TM , a polymer linked platinum cancer drug is in Phase clinical testing in cancer patients, as is Phenylbutyrate, a pleotropic agent which current evidence suggests acts as both an HDAC inhibitor and a differentiating agent. The Company s preclinical development programs include Angiolix, a humanized monoclonal antibody which acts as an anti angiogenesis factor and is potentially targeted to a number of tumor types, including breast and ovarian Prodrax, a non toxic prodrug which is activated in the hypoxic zones of solid tumors to kill tumor cells Alchemix, a chemotherapeutic agent that combines two modes of action to overcome drug resistance, and oral insulin, which utilizes the company s Cobalamin TM oral drug delivery technology.

 

 

 

Current Management

  • David P. Nowotnik / SVP, R amp D
  • Phillip Wise / VP, Bus. Dev. NonProfit , VP, Strategy
  • Stephen B. Thompson / Vice President, CFO
  • Christine Berni / IR
  • Jeffrey B. Davis / Director
    • Mr. Davis has served as one of our directors since March . Since December , Mr. Davis has been President and Chief Executive Officer of Access Pharmaceuticals, Inc. Since April , Mr. Davis has been President of SCO Financial Group LLC and financial principal of SCO Securities LLC, a NASDregistered broker dealer. Prior to cofounding SCO, Mr. Davis served as Senior Vice President and Chief Financial Officer of HemaSure, Inc., a publicly traded development stage healthcare technology company. Prior to that, Mr. Davis was Vice President, Corporate Finance, at Deutsche Bank AG and Deutsche Morgan Grenfell, both in the U.S. and Europe. Mr. Davis also served in senior marketing and product management positions at AT amp T Bell Laboratories, where he was also a member of the technical staff. Prior to that, Mr. Davis was involved in marketing and product management at Philips Medical Systems North America. Mr. Davis served previously as a Director of Bioenvision, Inc. and currently serves as a Director of Access Pharmaceuticals, Inc., a publicly traded company. Mr. Davis holds a B.S. in Biomedical Engineering from the College of Engineering, Boston University and an M.B.A. from the Wharton School of Business, University of Pennsylvania.

Current Share Structure

  • Market Cap: $928,009,371 - 05/11/2018
  • Issue and Outstanding: 47,226,940 - 03/15/2018

 


Recent Filings from (NASDAQ: ABEO)

Amendment to a previously filed 8-K
Filing Type: 8-K/AFiling Source: edgar
Filing Date: May, 14 2018
Simplified registration form
Filing Type: S-3Filing Source: edgar
Filing Date: May, 11 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 11 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 11 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 10 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 10 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 02 2018
Withdrawal of registration statement filed under the Securities Act
Filing Type: RWFiling Source: edgar
Filing Date: March, 16 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 16 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: March, 12 2018

 

 


Daily Technical Chart for (NASDAQ: ABEO)

Daily Technical Chart for (NASDAQ: ABEO)


Stay tuned for daily updates and more on (NASDAQ: ABEO)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: ABEO)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ABEO is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of ABEO and does not buy, sell, or trade any shares of ABEO. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/